Seeing Is Believing
Currently out of the existing stock ratings of Chalres Zhu, 405 are a BUY (77.14%), 115 are a HOLD (21.9%), 5 are a SELL (0.95%).
Analyst Chalres Zhu, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 22.22% that have a potential upside of 9.64% achieved within 44 days.
Chalres Zhu’s has documented 38 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on MGNX, MacroGenics at 23-Nov-2022.
Analyst best performing recommendations are on ZYME (ZYMEWORKS . COMMON STOCK).
The best stock recommendation documented was for ZYME (ZYMEWORKS . COMMON STOCK) at 11/20/2019. The price target of $48 was fulfilled within 58 days with a profit of $9.24 (23.84%) receiving and performance score of 4.11.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$10
$6.89 (221.54%)
$10
13 days ago
(08-Nov-2024)
0/17 (0%)
$6.42 (179.33%)
Buy
$25
$21.89 (703.86%)
$30
1 years 1 months 5 days ago
(16-Oct-2023)
2/6 (33.33%)
$19.91 (391.16%)
141
Buy
$17
$13.89 (446.62%)
$16
1 years 1 months 27 days ago
(25-Sep-2023)
1/5 (20%)
$4.3 (33.86%)
6
Buy
$28
$24.89 (800.32%)
$43
1 years 6 months 11 days ago
(10-May-2023)
0/2 (0%)
$17.42 (164.65%)
$14
$10.89 (350.16%)
$15
1 years 8 months 25 days ago
(27-Feb-2023)
1/5 (20%)
$3.45 (32.70%)
147
What Year was the first public recommendation made by Chalres Zhu?